Continuous glucose monitoring,
does it really help with Improved glycemic control in type 2 diabetes treated with basal insulin?
research showsContinuous glucose monitoring is rated C in people with type 2 diabetes using basal insulin because the validated effects are limited to surrogate outcomes. MOBILE (Martens 2021, JAMA) included 175 participants and found an HbA1c difference of -0.4 percentage points (95% CI -0.8 to -0.1). Severe hypoglycemia occurred once in each group, so no benefit can be claimed, and quality of life was not a confirmatory successful endpoint. Dexcom funded the study. Rule ①-ⓐ caps surrogate-only evidence at C with 55 points.
ads claimMarketing can equate real-time curves with proven prevention of complications and imply that finger-stick confirmation is never needed. The trial directly established only eight-month HbA1c and sensor-metric improvement.
Useful facts when choosing a product
- A continuous monitor measures interstitial rather than blood glucose, so lag and error can occur during rapid change.
- When symptoms and sensor readings disagree or glucose is changing rapidly, meter confirmation may be needed according to the product instructions.
- Insertion pain, bleeding, adhesive dermatitis, alarm fatigue, cost, and data-access problems can occur.
What the research actually shows
MOBILE (Martens 2021, JAMA) assigned 175 adults with type 2 diabetes treated with basal but no prandial insulin. The adjusted HbA1c difference was -0.4 percentage points (95% CI -0.8 to -0.1), and continuous-monitoring metrics improved. Severe hypoglycemia occurred once in each group, so no effect can be claimed, and quality of life was not a confirmatory successful endpoint. The validated direct effects are limited to HbA1c and continuous-monitoring metrics, both surrogates. Dexcom funded the study and supplied devices. verdict 1398, which is C with 42 points, concerns continuous monitoring in people without diabetes and has a different target population; its evidence was not used here.
Why this is classified as C (55)
The primary HbA1c endpoint and sensor metrics succeeded in the target MOBILE population, but surrogate-only outcomes, eight-month duration, manufacturer funding and device provision, and no long-term clinical events invoke rule ①-ⓐ and give C with 55 points.
Counterpoint. It is an effective tool for reviewing patterns and adjusting basal insulin and behavior with a clinician.
Rejudgment record. Cross-check applied — A successful HbA1c primary endpoint in the basal-insulin target population, with rule ①-ⓐ limiting the grade to C because only HbA1c and time-in-range surrogates were assessed, the manufacturer funded and supplied devices, and long-term clinical events were absent
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced HbA1c | C | The MOBILE primary endpoint succeeded by -0.4 percentage points, but it is a surrogate. |
| Increased time in range | C | It improved to 59% versus 43% at eight months, but remains a sensor surrogate. |
| Reduced hyperglycemic exposure | C | Continuous-monitoring metrics were positive but were not directly linked to fewer long-term complications. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Martens T et al. 2021 MOBILE | Multicenter open randomized controlled trial | 1 | Dexcom provided study funding and devices and participated in design development; one company employee was a coauthor | Primary endpoint of HbA1c at eight months | Primary endpoint succeeded: adjusted difference -0.4 percentage points (95% CI -0.8 to -0.1), P=.02. | Pivotal surrogate-endpoint trial in the target population |
| Beck RW et al. 2017 DIAMOND T2D | Multicenter open randomized controlled trial | 24 | Supported by Dexcom with device provision and manufacturer-affiliated authors | Primary endpoint of HbA1c at 24 weeks | Replicated HbA1c improvement, but multiple daily injections including prandial insulin make it indirect for the basal-only population. | Replicating evidence with population indirectness |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Continuous glucose monitoring x glycemic control with basal insulin in type 2 diabetes — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/continuous-glucose-monitor-basal-insulin-type-2-diabetes-glycemic-control/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.